daratumumab - Robuta Search

https://www.darzalexhcp.com/ HCP Website | DARZALEX® & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) hcp website darzalex daratumumab hyaluronidase https://www.darzalex.com/ Official Patient Website | DARZALEX® & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) patient website official darzalex daratumumab hyaluronidase https://www.jnj.com/media-center/press-releases/daratumumab-combination-therapy-improved-clinical-outcomes-regardless-of-cytogenetic-risk-for-previously-treated-patients-with-multiple-myeloma Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for... combination therapy clinical outcomes daratumumab improved https://adisinsight.springer.com/drugsafety/803928687?error=cookies_not_supported&code=9e4607c9-ec49-4c8f-b332-a5805ba24a52 Daratumumab - AdisInsight A patient [age and sex not stated] with cardiac AL amyloidosis received first-line Dara-CyBorD [dose, route and duration not stated] and experienced daratumumab adisinsight https://ce.massmed.nejm.org/nejm-weekly-cme/content/daratumumab-or-active-monitoring-high-risk-smoldering-multiple-myeloma Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | MMS/NEJM Continuing... https://open.library.emory.edu/concern/publications/efa66ab7-49c3-4ce1-85b6-0e7d0faf2d24 Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in... Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma patient characteristics https://open.library.emory.edu/concern/publications/f74958c1-7886-4121-b6f2-70179f941c84 Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple... Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study... for patients daratumumab https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-carfilzomib-and-daratumumab-for-myeloma-candor A study of carfilzomib and daratumumab for myeloma (CANDOR) This study is for people whose myeloma has come back or whose treatment has stopped working. a study carfilzomib daratumumab myeloma candor https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-00594 A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the... A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple... a study the addition https://pubmed.ncbi.nlm.nih.gov/29411874/ Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in... Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma efficacy and safety https://adisinsight.springer.com/drugsafety/803928477?error=cookies_not_supported&code=e7924d04-2066-40d7-b8c1-60ca3efb8186 Daratumumab - AdisInsight Seventeen patients [age and sex not stated] receiving daratumumab [route, dosage and duration not stated], an anti-CD38 monoclonal antibody, experienced daratumumab adisinsight https://adisinsight.springer.com/drugsafety/803383410?error=cookies_not_supported&code=cc6d9d39-3625-4704-9e03-46d57ce3c82a Daratumumab linked with HBV reactivation, some fatalities - AdisInsight Daratumumab is linked with rare cases of hepatitis B virus (HBV) reactivation, in some cases fatal, in patients with multiple myeloma, according to Health daratumumab linked hbv reactivation fatalities https://pubmed.ncbi.nlm.nih.gov/27216216/ Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or... The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. Here, we present an updated pooled... clinical efficacy https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-daratumumab-standard-treatment-children-young-adults-acute-lymphoblastic-leukaemia-lymphoblastic-lymphoma-delphinus-trial Cancer Research UK | A trial looking daratumumab and standard treatment for children and young... This trial is for children and young people whose leukaemia or lymphoma has come back or treatment has stopped working. cancer research uk https://adisinsight.springer.com/trials/700367548?error=cookies_not_supported&code=c22c569b-3fba-4d8a-ab50-3b05adcc0203 Phase IIa Study to Evaluate Daratumumab for Polyneuropathy Associated With MGUS - AdisInsight The goal of this clinical trial is to learn about daratumumab and hyaluronidase-fihj in patients with monoclonal gammopathy of undetermined significant (MGUS) https://scholars.duke.edu/publication/1553044 Scholars@Duke publication: Unexpected Serologic Results Following DTT Treatment in Daratumumab... scholars duke publication unexpected https://adisinsight.springer.com/trials/700357445?error=cookies_not_supported&code=e6f68ff7-8525-424a-a820-ed7314385d0e A Investigator-initiated Clinical Trial to Assess Safety and Efficacy of Daratumumab in the... A single-center, open-label, off-label use investigator-initiated clinical study to explore the clinical activity and safety of daratumumab in adult ITP https://open.library.emory.edu/concern/publications/9af85a1a-edb6-4f09-aa9f-a39ef5df5735 Daratumumab induces mechanisms of immune activation through CD38+NK cell targeting | OpenEmory Daratumumab induces mechanisms of immune activation through CD38+NK cell targeting https://adisinsight.springer.com/drugsafety/803446262?error=cookies_not_supported&code=b5e2e23f-f7cd-4db5-b398-823c99d40120 Daratumumab/pomalidomide - AdisInsight A 72-year-old man developed fatal multi-organ failure (MOF) secondary to fulminant haemophagocytic lymphohistiocytosis (HLH) during treatment with daratumumab daratumumab pomalidomide adisinsight https://pubchem.ncbi.nlm.nih.gov/compound/Daratumumab_-hyaluronidase-fihj Daratumumab; hyaluronidase-fihj - PubChem Daratumumab; hyaluronidase-fihj chemical information summary. daratumumab hyaluronidase pubchem https://seer.cancer.gov/oncologytoolbox/canmed/hcpcs/1462/ C9062 Daratumumab Hyaluronidase - CanMED: HCPCS CanMED: HCPCS. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies. daratumumab hyaluronidase hcpcs https://www.cancer.gov/publications/dictionaries/cancer-terms/def/daratumumab Definition of daratumumab - NCI Dictionary of Cancer Terms - NCI NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. definition of daratumumab nci dictionary cancer https://www.jnj.com/media-center/press-releases/daratumumab-expanded-access-program-open-to-eligible-us-patients-with-heavily-pre-treated-multiple-myeloma Daratumumab Expanded Access Program Open to Eligible U.S. Patients with Heavily Pre-Treated... Feb 8, 2024 - Janssen, with support from the Multiple Myeloma Research Foundation, opens EAP to help patients in immediate need of new treatment options https://epflicht.ulb.uni-bonn.de/content/titleinfo/704827 E-Pflicht-Sammlung / Daratumumab (neu diagnostiziertes multiples Myelom, Stammzelltransplantation... Home. Daratumumab (neu diagnostiziertes multiples Myelom, Stammzelltransplantation nicht geeignet) - Addendum zum Auftrag A21-126 : Addendum : Auftrag: A22-27... multiples myelom pflicht sammlung daratumumab neu https://adisinsight.springer.com/drugsafety/803453619?error=cookies_not_supported&code=c80eb505-c758-43da-b915-4924ce5f11d6 Daratumumab/dexamethasone/lenalidomide - AdisInsight A 63-year-old man developed cytomegalovirus (CMV) infections including CMV viremia and CMV retinitis during treatment with lenalidomide, daratumumab and daratumumab dexamethasone lenalidomide adisinsight https://www.techtransfer.nih.gov/tech/tab-4505 Blocking CD38 using Protein G Complexed Daratumumab Antibodies (PGDARA) to Protect Natural Killer... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT04268498&r=1 Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed... Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma for the daratumumab carfilzomib lenalidomide dexamethasone https://experts.mcmaster.ca/scholarly-works/2176067 Efficacy of Daratumumab-Containing Regimens Among... Learn about the scholarly work entitled Efficacy of Daratumumab-Containing Regimens Among... efficacy daratumumab containing regimens among https://adisinsight.springer.com/drugsafety/803929328?error=cookies_not_supported&code=1489011c-932f-4b6f-a721-1e707d421ad9 Daratumumab - AdisInsight In this report, four patients [ages and sexes not stated] with biopsy-proven anti-PLA2R-associated membranous nephropathy and high-risk nephrotic syndrome with daratumumab adisinsight https://pharma.economictimes.indiatimes.com/tag/daratumumab Daratumumab - Latest daratumumab , Information & Updates - Pharma -ETPharma ETPharma.com brings latest daratumumab news, views and updates from all top sources for the Indian Pharma industry. latest information daratumumab updates pharma https://www.cochrane.org/ms/evidence/CD013595_what-are-benefits-and-harms-daratumumab-addition-antimyeloma-medicines-compared-antimyeloma Apakah faedah dan kemudaratan daratumumab sebagai tambahan kepada ubat antimieloma berbanding ubat... apakah faedah dan daratumumab